Browse by ▼

Pfizer

  • This Promising Biotech Can Triple

    By Mohsin Saeed - June 19, 2013 | Tickers: ONCY, PFE, TEVA

    Cancer is one of the deadliest challenges that humans face today. Different forms of cancer have taken millions of lives all around the world. According to studies, every year approximately 7.5 million patients are diagnosed with cancer. This also presents a massive commercial opportunity for healthcare companies making cancer drugs.

    Recent studies have revealed that viruses are the best way to treat cancers. Some specific viruses attack the cancer more »

  • "Pay-For Delay" Was Fun While It Lasted

    By Sherrie Stone - June 18, 2013 | Tickers: ABBV, ACT, PFE

    When the FTC and the U.S. Supreme Court start breathing down your neck it’s not a pleasant thing, and could become very expensive for certain companies. Yet, not many people are talking about the trouble that generic and brand-name drug makers are finding themselves in.

    Uncovering a costly practice

    Last year, the FTC uncovered a number of agreements between large pharma and generic drug companies, which it called more »

  • Is This Stock A Buy After Giant Acquisition?

    By Nur Tarkak - June 18, 2013 | Tickers: JNJ, NVS, PFE, PG

    Johnson & Johnson (NYSE: JNJ) announced on Monday, June 17, that it is buying Aragon Pharmaceuticals, a privately-held drug company. Shares of Johnson & Johnson moved slightly higher right after the announcement was made. The transaction is estimated to cost Johnson & Johnson approximately $1 billion. About $650 million will be in the form of upfront cash payment. The remaining $350 million will be paid after Aragon Pharma meets certain milestones.

    Aragon Pharma more »

  • Big Pharma's Intellectual Property Blues

    By Leo Sun - June 18, 2013 | Tickers: MYGN, NVS, PFE

    It’s not easy being a biotech company. Every year, the biotech industry pours billions of dollars in research and development costs towards creating cutting edge drugs that treat major diseases. If these drugs are approved, then they are patented, sometimes becoming best-selling medications that generate even more revenue to aid further research.

    However, when these big pharmaceutical companies create tests and drugs that can treat major, life-threatening diseases such more »

  • Huge Upside on Pipeline Strength

    By Mohsin Saeed - June 17, 2013 | Tickers: AMGN, GILD, PFE

    Amgen (NASDAQ: AMGN) is the world’s largest independent biotechnology company. It has managed to produce a string of successful drugs and still has one of the richest pipelines in the entire healthcare sector. The shares have appreciated significantly during the last 52 weeks, but the strong pipeline demands even better valuations. A number of catalysts are approach which can significantly improve the company’s valuations and reinforce its long more »

  • Hedge Fund Brahman Capital Bets Big on This Pharma Stock

    By Meena Krishnamsetty - June 14, 2013 | Tickers: ABT, ENDP, GILD, PFE, TEVA

    A 13G filed with the SEC has disclosed that Brahman Capital, a hedge fund managed by Peter Hochfelder and his team, owns 6.3 million shares of Endo Health Solutions (NASDAQ: ENDP), a $4.3 billion market cap pharmaceutical company. We track quarterly 13F filings from hedge funds such as Brahman as part of our work researching investment strategies (we have found, for example, that the most popular small cap more »

  • Strong Product Pipelines Have Pharmaceutical Companies Poised for Growth

    By Colin Tweel - June 14, 2013 | Tickers: AZN, PFE, PBYI

    With the global economy beginning to stabilize, the stock market is looking more attractive than ever. One industry that could stand to make huge gains in the near future is the pharmaceutical industry, though it's worth noting that this sector is a high risk, high reward industry. Still, pharmaceutical stocks offer a great way to diversify your portfolio and add stocks with high potential. Yes, there are risks involved more »

  • 5 Biotech Giants with Lucrative Dividend Yields

    By Nur Tarkak - June 13, 2013 | Tickers: AZN, GSK, MRK, NVS, PFE

    Investing in biotech stocks is relatively risky amid the volatility of the market. There are many factors that can greatly affect share trends and price performance. Biotech companies go through a series of clinical trials toward FDA approval and market launch. Any update of the trial can potentially cause the shares to shoot up or go down. Competitors’ activities and drug issues can affect the shares, as well.

    The triumphs more »

  • Is Concentration Better Than Diversification in Pharma?

    By Nicholas Kitonyi - June 13, 2013 | Tickers: AZN, PFE, ZTS

    Pfizer (NYSE: PFE) recently completed the spin-off of its animal health unit, Zoetis (NYSE: ZTS). The company offered to acquire its stake in Zoetis for a 7% discount, in exchange of all or part of its shareholding. This is subject to an upper limit of 0.9898 shares of Zoetis common stock per share of Pfizer common stock. This spin-off is expected to reflect on Pfizer’s EPS beginning 2014 more »

  • Billionaire Paul Tudor Jones' Latest Additions

    By Marshall Hargrave - June 12, 2013 | Tickers: A, BKD, PFE, WLP

    Billionaire Paul Tudor Jones (PTJ) has been all over the news  after telling an audience of University of Virginia students and others that it's difficult for mothers to be successful traders given that their connection to a child is a focus "killer." PTJ has been one of the most successful traders over the past few decades, with a net worth of some $3.3 billion. Let's check out more »

  • Juicy Dividends From the Three Pharmaceutical Giants

    By Anh HOANG - June 12, 2013 | Tickers: MRK, NVS, PFE

    Merck & Co (NYSE: MRK) has been trying to generate more value for its shareholders via its share buyback program. Recently, it has also had a repurchase agreement to buy back its shares held by Goldman Sachs, with a total transaction value of as much as $5 billion. It was reported that the transaction would be expected to finish by the end of November within this year. Since the beginning of more »

  • Is Pfizer a Buy?

    By Robert Ciura - June 11, 2013 | Tickers: BMY, LLY, PFE

    The biggest pharmaceutical companies in the United States are in an enviable position. They sell products that are literally a matter of life and death. People who take medication will pay for it no matter what, and will often cut back on many other necessary expenses if need be.

    As a result it should be no surprise that some of the market’s best performers last year came from the more »

  • Looking to Return Capital to Shareholders Via Debt-Fueled Share Buyback

    By Mike Thiessen - June 11, 2013 | Tickers: AZN, MRK, PFE

    Pharmaceutical giant Merck (NYSE: MRK) recently announced plans to mount a massive $15 billion share buyback program that would result in the cancellation of up to 10 percent of its total share float. Although many large companies have recently announced plans to return capital to their shareholders via similar buybacks, this stands as one of the largest such moves to date. In a measure of its import, Merck has notified more »

  • Billionaire Ken Fisher’s Cheap Stock Picks

    By Meena Krishnamsetty - June 11, 2013 | Tickers: AAPL, HBC, JPM, PFE, WFC

    Billionaire Ken Fisher, a long-running columnist for Forbes, also runs the asset manager Fisher Asset Management. We track this fund’s activities alongside those of hundreds of hedge funds and other notable investors, using their quarterly 13F filings to help us develop investment strategies; we have found, for example, that the most popular small cap stocks among hedge funds earn an average excess return of 18 percentage points per year more »

  • Billionaire David Shaw’s Cheap Stock Picks

    By Meena Krishnamsetty - June 11, 2013 | Tickers: AAPL, XOM, MPC, PFE, WFC

    We track quarterly 13F filings from hundreds of hedge funds and other notable investors, including billionaire David Shaw’s large hedge fund D.E. Shaw. While one way to make use of this information is to compile 13Fs and use them to develop investment strategies (we have found, for example, that the most popular small cap stocks among hedge funds earn an average excess return of 18 percentage points per more »

  • Celgene’s Abraxane: A Therapy for Advanced Pancreatic Cancer?

    By Kanak Kanti - June 10, 2013 | Tickers: CELG, NVS, PFE

    Celgene’s (NASDAQ: CELG) Abraxane is primarily used to treat breast and lung cancer. It is a very lucrative drug for the company with almost half a billion dollars in sales last year alone. It is prospectively going to become even more lucrative as studies are ongoing to see if the drug is also effective against pancreatic tumors. The FDA has also granted Abraxane priority review instead of the normal more »

  • Billionaire Stanley Druckenmiller's Big 5

    By Marshall Hargrave - June 8, 2013 | Tickers: DHI, LLY, GOOG, LEN, PFE

    Billionaire Stanley Druckenmiller founded his Duquesne Capital hedge fund in 1981. It now has some $10 billion in assets under management. Previously, Druckenmiller managed money for George Soros from 1988 to 2000, and was the lead portfolio manager for Soros' famous Quantum Fund. Outlined below are Druckenmiller's top five stocks going into the second quarter, let's check them out (see Druckenmiller's selloffs).
     
    Housing bets
     
    Druckenmiller's top more »

  • AstraZeneca’s Acquisition of Omthera Pharma Is a Desperate Act

    By Nicholas Kitonyi - June 8, 2013 | Tickers: AMRN, AZN, GSK, OMTH, PFE

    AstraZeneca (NYSE: AZN) announced the acquisition of Omthera Pharmaceuticals (NASDAQ: OMTH), a company that went public just last month (April 11). Omthera listed a price of $8 per share, and has since struggled to breach that mark until AstraZeneca came up with an offer to acquire the company. Omthera is a specialty drug maker with a keen focus on patients who have high levels of fats, called triglycerides, in their more »

  • Big Things Are Happening at This Pharmaceutical Company

    By Timothy Green - June 7, 2013 | Tickers: LLY, MRK, PFE

    Pharmaceutical company Pfizer (NYSE: PFE) has been doing some interesting things lately. The company has been shedding its non-pharmaceutical assets in order to focus on its core business which carries high profit margins. In April 2012, Pfizer sold its infant nutrition business to Nestle, and this February, the company spun off its animal health business Zoetis.

    Pfizer's stock has fallen more than 10% from its high in April, pushing more »

  • Which Generic Drugmaker Is Your Best Buy Today?

    By Brendan O'Boyle - June 6, 2013 | Tickers: ACT, MYL, PFE, TARO

    Generic-drug makers have considerable tailwinds, making their outperformance in the past year unsurprising.  However, most companies within this sub-industry are both cheap and relatively unknown -- a combination which bodes well for investors. Here, we'll review three generic-drug makers that still trade at appealing valuations.

    How the generics game works

    Prescription drugs are split into two categories: generic and brand-name. Pharmaceutical companies develop their products through a laborious and risky more »

  • Page 1 of 22